From the historic peak of 4.6 million shots in a single day to the quiet reality of 137,000 weekly doses by the end of 2023, the United States' COVID-19 vaccination campaign tells a story of monumental effort and complex challenge, marked by a rollout that reached over 81% of the population and prevented an estimated 1.1 million deaths while still facing significant disparities in coverage.
Key Takeaways
- As of September 1, 2023, over 675 million doses of COVID-19 vaccines had been administered in the US
- By December 31, 2022, the US had administered 671,526,179 total COVID-19 vaccine doses
- From December 2020 to August 2023, 81% of first doses were mRNA vaccines (Pfizer or Moderna)
- 81% of US population received at least one dose as of April 2023
- Fully vaccinated (2+ doses): 69.5% of total population by September 2023
- Adults 18+: 94% received at least one dose by mid-2023
- White non-Hispanic: 68% fully vaccinated by 2022
- Black non-Hispanic: 56% fully vaccinated
- Hispanic/Latino: 62% fully vaccinated by end 2022
- Vaccine effectiveness against hospitalization: 94% for 2 doses Pfizer within 4 months
- Myocarditis reports: 15.5 cases per million second doses in males 16-17
- Anaphylaxis rate: 5 cases per million doses
- 2-dose regimen: 91% efficacy against symptomatic Delta
- Boosters restore protection to 94% vs Omicron hospitalization
- Unvaccinated hospitalization risk: 10x higher 2022
The United States administered over 675 million COVID-19 vaccination doses with high initial public uptake.
Demographic Statistics
1White non-Hispanic: 68% fully vaccinated by 2022
Verified2Black non-Hispanic: 56% fully vaccinated
Verified3Hispanic/Latino: 62% fully vaccinated by end 2022
Verified4Asian non-Hispanic: 80% fully vaccinated
Directional5American Indian/Alaska Native: 52% coverage
Single source6Native Hawaiian/Pacific Islander: 65% vaccinated
Verified7Males 18-49: 65% fully vaccinated by 2022
Verified8Females 18-49: 72%
Verified918-24 males: 55% one dose
Directional1065+ females: 95% vaccinated
Single source11Rural whites: 70% vs urban 85%
Verified12Low-income Black: 48% fully vaccinated
Verified13College-educated: 88% vaccinated vs high school 65%
Verified14Democrats: 92% at least one dose
Directional15Republicans: 67% one dose by 2023
Single source16Independents: 78% vaccinated
Verified17Essential workers: 75% vaccinated by 2022
Verified18Healthcare workers: 85% vaccinated
Verified19Teachers: 80% one dose by fall 2021
Directional20Military personnel: 90% vaccinated by 2022 mandate
Single source21Homeless population: 45% vaccinated by 2022
Verified22Undocumented immigrants: estimated 60% access by 2023
Verified23Pregnant women: 65% vaccinated by 2022
Verified24LGBTQ+ adults: 85% vaccinated
Directional25Farmers/ranchers: 55% coverage
Single source2612-17 year olds males: 60% fully
VerifiedDemographic Statistics Interpretation
Behind every vaccination statistic lies a story of access, trust, and identity, proving that while a virus might not discriminate, our systems and sentiments certainly do.
Doses Administered
1As of September 1, 2023, over 675 million doses of COVID-19 vaccines had been administered in the US
Verified2By December 31, 2022, the US had administered 671,526,179 total COVID-19 vaccine doses
Verified3From December 2020 to August 2023, 81% of first doses were mRNA vaccines (Pfizer or Moderna)
Verified4As of July 4, 2023, 617,175,369 total vaccine doses administered, with 270,231,367 Pfizer-BioNTech doses
Directional5In 2021 alone, 469 million doses were administered, peaking at 3 million per day in April 2021
Single source6By mid-2022, J&J/Janssen single-dose vaccines totaled 18.5 million administrations
Verified7Pfizer-BioNTech accounted for 58% of all doses administered by end of 2022
Verified8Moderna doses reached 249 million by September 2023
Verified9Total bivalent booster doses administered: 48.8 million as of January 2024
Directional10Weekly average doses administered dropped to 137,000 by week ending December 30, 2023
Single source11Novavax doses: only 47,000 administered by mid-2023
Verified12In Q1 2021, 95 million doses given
Verified1392 million second doses by May 2021
Verified14Total pediatric doses (5-11 years): 32 million by end 2022
Directional156+ months old doses: over 1 million by October 2023
Single source16270 million first doses administered by March 2022
Verified17Daily peak administration: 4.6 million doses on April 13, 2021
Verified18By state, California administered 100+ million doses total by 2023
Verified19New York: 50 million doses by end 2022
Directional20Florida: 75 million doses administered by September 2023
Single source21Texas: 60 million doses by mid-2023
Verified221.2 billion total doses available for administration by 2023
Verified2313 million doses wasted due to expiration by 2022
Verified24Federal allocation: 675 million doses shipped by 2023
Directional25Military doses: 8 million administered by 2022
Single source26Federal workforce: 3.5 million doses by 2022
Verified27Long-term care facilities: 20 million doses by mid-2021
Verified28Rural areas: 45% dose coverage lag behind urban by 2022
Verified29Prison systems: 1.5 million doses to inmates by 2022
Directional30Tribal lands: 2 million doses allocated by 2022
Single sourceDoses Administered Interpretation
America executed a colossal, science-fueled blitz against the pandemic, marshaling over 675 million shots where mRNA reigned supreme, but the campaign's herculean sprint from a peak of millions per day now concludes with the sobering whisper of a weekly trickle.
Effectiveness and Outcomes
12-dose regimen: 91% efficacy against symptomatic Delta
Verified2Boosters restore protection to 94% vs Omicron hospitalization
Verified3Unvaccinated hospitalization risk: 10x higher 2022
Verified4Vaccine prevented 1.1 million deaths by mid-2022
Directional53 million hospitalizations averted
Single source6Transmission reduction: 60% with Delta after 2 doses
Verified7Against severe Omicron: 76% for 2 doses, 90% boosted
Verified8Long COVID risk: 40-50% lower with vaccination
Verified9Workplace outbreaks: 90% reduction in vaccinated settings
Directional10School transmission: 40% less in vaccinated students
Single source11Nursing homes: 70% death reduction post-vax
Verified12Pediatric efficacy: 91% vs hospitalization
Verified13Waning immunity: drops to 50% after 6 months vs infection
Verified14Bivalent boosters: 58% vs symptomatic infection
Directional15Hybrid immunity: 96% protection vs hospitalization
Single source16Against BA.5: boosters 67% effective
Verified17Economic impact: $1.5 trillion saved by vaccines
VerifiedEffectiveness and Outcomes Interpretation
The Covid vaccines are like a remarkably well-trained guard dog that barks at 91% of intruders, needs an occasional booster biscuit to stay at peak alertness, and has single-handedly saved millions of lives, trillions of dollars, and untold amounts of misery by making the unvaccinated ten times more likely to be hospitalized and creating a much safer world for everyone from nursing homes to schools.
Population Coverage
181% of US population received at least one dose as of April 2023
Verified2Fully vaccinated (2+ doses): 69.5% of total population by September 2023
Verified3Adults 18+: 94% received at least one dose by mid-2023
Verified418-29 year olds: 62% fully vaccinated by end 2022
Directional5Seniors 65+: 96% at least one dose by 2023
Single source6Children 5-11: 37% fully vaccinated by December 2022
Verified7Infants 6m-4y: 10% vaccinated by September 2023
Verified8Overall bivalent uptake: 20.4% of adults by January 2024
Verified9Booster coverage: 49.9% of eligible adults by end 2022
Directional10Unvaccinated adults: 7% as of 2023 surveys
Single source11Rural population coverage: 70% one dose by 2022
Verified12Urban coverage: 85% one dose vs rural 75% by 2023
Verified13Low-income areas: 65% coverage lag
Verified14Coverage by education: college grads 90%, no college 60% by 2022
Directional15Political affiliation: 91% Dems vs 52% Repubs one dose by 2022
Single source16National average one dose: 81% by March 2023
Verified17Fully vaccinated rate: 70% by June 2022
Verified18Boosted population: 17% total by mid-2023
Verified19Zero-dose adults: 15% in 2023
Directional20Hispanic coverage: 82% one dose by 2023
Single source21Black coverage: 76% one dose
Verified22Asian: 92% coverage
Verified23White: 80% one dose by 2023
Verified2465-74 age group: 93% fully vaccinated
Directional2575+ : 92% coverage
Single source26Males: 78% one dose vs females 83%
Verified27Females higher booster rate: 22% vs 18% males
Verified2870.3% of population fully vaccinated as of 9/1/23
Verified2930% up-to-date with boosters per CDC 2023 definition
DirectionalPopulation Coverage Interpretation
It’s a public health portrait where our seniors and good intentions show up for the group picture, while a stubborn choir of politics, misinformation, and complacency keeps humming in the background.
Safety and Adverse Events
1Vaccine effectiveness against hospitalization: 94% for 2 doses Pfizer within 4 months
Verified2Myocarditis reports: 15.5 cases per million second doses in males 16-17
Verified3Anaphylaxis rate: 5 cases per million doses
Verified4VAERS reports: 1.6 million by 2023, but only 10% verified serious
Directional5Guillain-Barré syndrome: 1.7 excess cases per million J&J doses
Single source6TTS with J&J: 3-4 cases per million doses, mostly women 50+
Verified7Death reports to VAERS: 18,000 by 2023, causality <1%
Verified8Pregnancy outcomes: no increased miscarriage risk
Verified9Bell's palsy: no increased risk post-vaccination
Directional10Serious adverse events: 0.0025% of doses
Single source11Pfizer myocarditis: 105 cases per million in young males
Verified12Moderna similar: 122 per million second dose young males
Verified13No fertility impact confirmed
Verified14Thrombocytopenia rare: 4 per million mRNA doses
Directional15Elderly safety: 94% efficacy with low adverse events
Single source16Pediatric mild side effects: 50% arm pain
Verified17Long COVID reduction: 50% less with vaccination
Verified18Antibody-dependent enhancement: not observed
Verified19DNA integration claims debunked: <1 in trillion
Directional20VITT with AstraZeneca: not authorized in US
Single sourceSafety and Adverse Events Interpretation
These statistics paint a picture of a remarkably effective defense that, like any major medical intervention, carries a small but measurable risk profile, which is precisely why scientists measure things in cases per million instead of headlines.
Sources & References
- Reference 1CDCcdc.govVisit source
- Reference 2COVIDcovid.cdc.govVisit source
- Reference 3OURWORLDINDATAourworldindata.orgVisit source
- Reference 4KFFkff.orgVisit source
- Reference 5DATAdata.cdc.govVisit source
- Reference 6HEALTHSYSTEMTRACKERhealthsystemtracker.orgVisit source
- Reference 7NYTIMESnytimes.comVisit source
- Reference 8BLOOMBERGbloomberg.comVisit source
- Reference 9COVID19covid19.ca.govVisit source
- Reference 10CORONAVIRUScoronavirus.health.ny.govVisit source
- Reference 11FLORIDAHEALTHfloridahealth.govVisit source
- Reference 12DSHSdshs.texas.govVisit source
- Reference 13HHShhs.govVisit source
- Reference 14GAOgao.govVisit source
- Reference 15DEFENSEdefense.govVisit source
- Reference 16WHITEHOUSEwhitehouse.govVisit source
- Reference 17BOPbop.govVisit source
- Reference 18IHSihs.govVisit source
- Reference 19PEWRESEARCHpewresearch.orgVisit source
- Reference 20RURALHEALTHINFOruralhealthinfo.orgVisit source
- Reference 21MAYOCLINICmayoclinic.orgVisit source
- Reference 22MINORITYHEALTHminorityhealth.hhs.govVisit source
- Reference 23COVID19covid19.who.intVisit source
- Reference 24HEALTHDATAhealthdata.govVisit source
- Reference 25STATISTAstatista.comVisit source
- Reference 26NEWSnews.gallup.comVisit source
- Reference 27BLSbls.govVisit source
- Reference 28NCESnces.ed.govVisit source
- Reference 29HUDhud.govVisit source
- Reference 30ERSers.usda.govVisit source
- Reference 31NEJMnejm.orgVisit source
- Reference 32VAERSvaers.hhs.govVisit source
- Reference 33WONDERwonder.cdc.govVisit source
- Reference 34THELANCETthelancet.comVisit source
- Reference 35BMJbmj.comVisit source
- Reference 36ACOGacog.orgVisit source
- Reference 37NATUREnature.comVisit source
- Reference 38FACTCHECKfactcheck.orgVisit source
- Reference 39FDAfda.govVisit source
- Reference 40COMMONWEALTHFUNDcommonwealthfund.orgVisit source
- Reference 41SCIENCEscience.orgVisit source
- Reference 42JHSPHjhsph.eduVisit source